Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sponsors’ Use Of Adaptive Designs Appears To Be Growing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A Drug Information Association working group survey found 477 studies between Jan. 1, 2008 and Sept. 1, 2011 utilized some type of adaptive design.

You may also be interested in...



Roche Oncology Trials Designed For “Learning On The Go”

Roche is innovating in the structure of clinical development to manage the increasingly complex knowledge of cancer biology, using adaptive trial designs and extensive analysis of responders to find biomarkers that can inform, adjust and enrich clinical studies in a continually iterative process of “learning on the go.”

R&D Productivity Still Lags: Study Shows Success Rates May Have Been Overestimated

Large study tracking drug indications pursued by more than 800 companies over almost a decade finds that only one in 10 wound up getting approved. By therapeutic area, Phase III success rates were lowest in cancer and cardiovascular medicine, and highest in diabetes, infectious and autoimmune disease.

Antibacterial Trials Can Benefit From Futility Analysis, Genentech Tells FDA

Adaptive designs and studies at multiple infection sites are among industry suggestions to the agency as possible new approaches to developing drugs to fight bacterial infections.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel